pyridoxine has been researched along with Alzheimer Disease in 8 studies
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source
vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pyridoxine is a water- soluble pyridine derivative." | 1.48 | Pyridoxine exerts antioxidant effects in cell model of Alzheimer's disease via the Nrf-2/HO-1 pathway. ( Chen, S; He, Y; Hu, C; Li, C; Ma, Q; Wang, H; Wang, R, 2018) |
| "Deferoxamine treatment may produce serious side effects that can be eliminated by modification of treatment and by control of deferoxamine metabolism." | 1.28 | Suppression of deferoxamine mesylate treatment-induced side effects by coadministration of isoniazid in a patient with Alzheimer's disease subject to aluminum removal by ionspecific chelation. ( Fisher, EA; Kruck, TP; McLachlan, DR, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Baswar, D | 1 |
| Sharma, A | 1 |
| Mishra, A | 1 |
| Li, C | 1 |
| Wang, R | 1 |
| Hu, C | 1 |
| Wang, H | 1 |
| Ma, Q | 1 |
| Chen, S | 1 |
| He, Y | 1 |
| Yang, X | 1 |
| Qiang, X | 1 |
| Li, Y | 1 |
| Luo, L | 1 |
| Xu, R | 1 |
| Zheng, Y | 1 |
| Cao, Z | 1 |
| Tan, Z | 1 |
| Deng, Y | 1 |
| Richard, E | 1 |
| Kuiper, R | 1 |
| Dijkgraaf, MG | 1 |
| Van Gool, WA | 1 |
| Ravaglia, G | 1 |
| Forti, P | 1 |
| Maioli, F | 1 |
| Vettori, C | 1 |
| Grossi, G | 1 |
| Bargossi, AM | 1 |
| Caldarera, M | 1 |
| Franceschi, C | 1 |
| Facchini, A | 1 |
| Mariani, E | 1 |
| Cavalli, G | 1 |
| Imagawa, M | 1 |
| Naruse, S | 1 |
| Tsuji, S | 1 |
| Fujioka, A | 1 |
| Yamaguchi, H | 1 |
| Agbayewa, MO | 1 |
| Bruce, VM | 1 |
| Siemens, V | 1 |
| Kruck, TP | 1 |
| Fisher, EA | 1 |
| McLachlan, DR | 1 |
1 trial available for pyridoxine and Alzheimer Disease
| Article | Year |
|---|---|
Vascular care in patients with Alzheimer's disease with cerebrovascular lesions-a randomized clinical trial.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Aspirin; Cerebrovascular Disorders; Cost-Benefi | 2009 |
7 other studies available for pyridoxine and Alzheimer Disease
| Article | Year |
|---|---|
In silico Screening of Pyridoxine Carbamates for Anti-Alzheimer's Activities.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Computer Si | 2021 |
Pyridoxine exerts antioxidant effects in cell model of Alzheimer's disease via the Nrf-2/HO-1 pathway.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Antioxidants; Cell Line, Tumor; HEK293 Cells; Hem | 2018 |
Pyridoxine-resveratrol hybrids Mannich base derivatives as novel dual inhibitors of AChE and MAO-B with antioxidant and metal-chelating properties for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Chelating Agents; Cholinesterase Inh | 2017 |
Elevated plasma homocysteine levels in centenarians are not associated with cognitive impairment.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Cognition Disorders; Cross-Sectional Studies; Dem | 2000 |
Coenzyme Q10, iron, and vitamin B6 in genetically-confirmed Alzheimer's disease.
Topics: Alzheimer Disease; Citric Acid; Coenzymes; Drug Therapy, Combination; Female; Ferrous Compounds; Hum | 1992 |
Pyridoxine, ascorbic acid and thiamine in Alzheimer and comparison subjects.
Topics: Alzheimer Disease; Ascorbic Acid; Female; Humans; Male; Nutritional Status; Pyridoxine; Thiamine; Th | 1992 |
Suppression of deferoxamine mesylate treatment-induced side effects by coadministration of isoniazid in a patient with Alzheimer's disease subject to aluminum removal by ionspecific chelation.
Topics: Aluminum; Alzheimer Disease; Chelation Therapy; Chromatography, High Pressure Liquid; Deferoxamine; | 1990 |